Pediatric rheumatic diseases present psychosocial challenges for patients and their families. These include (1) adjusting and coping with disease symptoms and limitations; (2) adhering to complex and demanding medical regimens; and (3) coping with chronic pain. This article reviews recent studies on these psychosocial issues for children with pediatric rheumatic diseases. There is a paucity of empirical studies addressing these issues and a clear need for multisite collaborative studies to address the psychosocial needs of patients and families.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00002281-200109000-00011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the clinical profiles and management of juvenile dermatomyositis in Africa: a survey of African rheumatology care providers.
Pediatr Rheumatol Online J
January 2025
Aga Khan University Medical College East Africa, Nairobi, Kenya.
Background: There are limited studies of juvenile dermatomyositis (JDM) in low and middle-income countries (LMIC). Many demonstrate delays to care, high prevalence of severe manifestations, and high mortality. Given the disease-associated damage with JDM, understanding JDM in Africa further is critical.
View Article and Find Full Text PDFRisk factors for growth retardation in children with juvenile idiopathic arthritis: a case-control study.
BMC Musculoskelet Disord
January 2025
Department of Pediatric, Hebei Medical University Third Hospital, 139 Ziqiang Road, Shijiazhuang City, 050051, Hebei Province, China.
Objective: This study aimed to investigate the role of various factors contributing to growth retardation, including nutritional intake, disease duration, and treatment history, and further identify key risk factors that may influence growth outcomes in patients with juvenile idiopathic arthritis (JIA).
Methods: Clinical data from 155 JIA children who were treated at our hospital between January 2019 and December 2022 were analyzed. The children were divided into the growth retardation group (n = 40) and the non-growth retardation group (n = 115) based on the height Z-score < -2 SD or not.
MAPK4 inhibits the early aberrant activation of B cells in rheumatoid arthritis by promoting the IRF4-SHIP1 signaling pathway.
Cell Death Dis
January 2025
Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
The involvement of B lymphocytes in the pathogenesis of rheumatoid arthritis (RA) is well-established, with their early and aberrant activation being a crucial factor. However, the mechanisms underlying this abnormal activation in RA remain incompletely understood. In this study, we identified a significant reduction in MAPK4 expression in both RA patients and collagen-induced arthritis (CIA) mouse models, which correlates with disrupted B cell activation.
View Article and Find Full Text PDFStopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
Lancet
January 2025
Francis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA; Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA; Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.
Background: Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.
View Article and Find Full Text PDFNeuropsychiatric manifestations in systemic lupus erythematosus and Sjogren's disease.
Autoimmun Rev
January 2025
Department of Orthopedics, Rheumatology and Traumatology-School of Medical Sciences, University of Campinas, Brazil; Autoimmunity Lab, School of Medical Sciences, University of Campinas, Brazil. Electronic address:
Introduction: Autoimmune diseases often present in a systemic manner, affecting various organs and tissues. Involvement of the central and peripheral nervous system is not uncommon in these conditions and is associated with high morbidity and mortality. Therefore, early recognition of the neuropsychiatric manifestations associated with rheumatologic diseases is essential for the introduction of appropriate therapies with the objective of providing a better quality of life for individuals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!